NRx Pharmaceuticals’ investigational antidepressant has failed to reach statistical significance in reducing depression severity in a phase 2/3 trial, though the biotech is pressing forward to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback